Biophytis SA Form 6-K — Nov 9, 2026
Biophytis SA announced the operational launch of its China joint venture, including creation of Biophytis Biopharmaceutical Shenzhen and a dedicated team to initiate the SARA-31 Phase 3 sarcopenia study in China. The JV brings together Biophytis and a consortium of Asian partners led by Ronghui Renhe Life Technology, with Biophytis holding 29% and the consortium 71%. Asian partners have committed up to $20 million over three years, with an expected $10 million in the first twelve months and a $3 million initial tranche payable once the Hong Kong JV framework and final licensing agreement are signed. The next step is a pre-IND submission to China's NMPA.
Key figures
- Sara31 patients china
- 642
- Sara31 patients japan
- 90
- Sara31 total patients
- 942
- Sara31 patients europe
- 200
- Financing commitment usd
- 20000000
- Jv board biophytis seats
- 3
- Jv board consortium seats
- 2
- Expected first 12 months usd
- 10000000
- Initial financing tranche usd
- 3000000
- Biophytis jv ownership percent
- 29
- Asian partners jv ownership percent
- 71
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.